Dr. Lal Path Labs financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹798cr+19.1% on Q1 FY26
Net profit
₹171cr+27.2% on Q1 FY26
EBITDA margin
31.0%+2.3 pts on Q1 FY26
EPS
₹10.15−36.1% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue798670+19.1%
EBITDA248192+28.7%
EBITDA margin31.0%28.7%+2.3 pts
Profit before tax229181+26.3%
Net profit171134+27.2%
EPS₹10.15₹15.88−36.1%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹798 crNet profit₹171 crNet margin21.4%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
32,218————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
665665619475414
33.133.133.836.133.2
0.00.00.083.3237
31,585————
2,8912,7632,4612,2272,017
—+12.2%+10.5%+10.4%—
838783696609490
29.0%28.3%28.3%27.4%24.3%
666621554466340
546510492362241
18.9%18.5%20.0%16.3%12.0%
₹32.33₹30.12₹29.06₹21.34₹14.25
—+3.6%+36.2%+49.7%—
—636569535456
—−173−53.9−57.5−44.6
462462515478411
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LALPATHLAB₹1,922.30

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,218 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————32,217.7
- Cash, Equiv & ST Investments413.6474.7619.3665.4665.4
+ Minority Interest33.236.133.833.133.1
+ Total Debt236.683.30.00.00.0
Enterprise Value————31,585.4
Revenue2,016.92,226.62,461.42,762.92,890.8
Growth %, YoY—+10.4+10.5+12.2—
EBITDA489.9609.3695.5782.5837.7
Margin %24.2927.3628.2628.3228.98
EBIT339.7465.7553.6620.7666.1
Net Income241.1362.3492.2509.8546.3
Margin %11.9516.2720.0018.4518.90
EPS, Adj (current shares)14.2521.3429.0630.1232.33
Growth %, YoY—+49.7+36.2+3.6—
Cash from Operations456.0535.4568.8635.7—
Capital Expenditures-44.6-57.5-53.9-173.4—
Free Cash Flow411.4477.9514.9462.3462.3
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Dr. Lal Path Labs financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Dr. Lal Path Labs (NSE: LALPATHLAB) had a market capitalisation of ₹32,040 crore at the 29 October 2026 close (₹1,911.70 a share), a PE ratio of 59.1 on the last four quarters' profit and a price-to-book ratio of 12.77. In FY26 its consolidated net profit attributable to shareholders was ₹505 crore on revenue of ₹2,763 crore; in Q1 FY27 (April–June 2026) it was ₹170 crore, up 28.0% year on year. It had no borrowings on 31 March 2026. Promoters held 52.93% of the shares on 30 September 2026.

Share price used
₹1,911.70 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Dr. Lal Path Labs at a glance · consolidated

Market cap
₹32,040 Crat ₹1,911.70 · 29 Oct close
PE ratio (last 4 quarters)
59.163.5 on FY26 profit
Price to book (PB)
12.77book value ₹149.65 a share
ROE (FY26)
21.6%−2.6 pts vs FY25ROCE 24.8%
Debt to equity
0.00net cash ₹1,332 Cr
Promoter holding
52.93%−0.3 pts vs 30 Jun 202630 September 2026
Net worth
₹2,508 Cr+15.4% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹462 Cr−10.2% vs FY25
EPS (FY26)
₹30.24

Questions

What is the Dr. Lal Path Labs PE ratio today?

Dr. Lal Path Labs' PE ratio is 59.1 at the 29 October 2026 close (₹1,911.70 a share): a market capitalisation of ₹32,040 crore divided by consolidated net profit attributable to shareholders of ₹542 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹505 crore) it is 63.5.

What is the Dr. Lal Path Labs PB ratio (price to book value)?

Dr. Lal Path Labs' price-to-book (PB) ratio is 12.77 at the 29 October 2026 close: a market capitalisation of ₹32,040 crore divided by shareholders' equity (book value) of ₹2,508 crore on 31 March 2026. That is a book value of ₹149.65 per share against a share price of ₹1,911.70.

What is the Dr. Lal Path Labs net worth?

Dr. Lal Path Labs' net worth — shareholders' equity in its consolidated balance sheet — was ₹2,508 crore on 31 March 2026, up 15.4% from ₹2,173 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹32,040 crore at the 29 October 2026 close.

What is the Dr. Lal Path Labs market cap?

Dr. Lal Path Labs' market capitalisation was ₹32,040 crore at the 29 October 2026 close: 16.76 crore shares at ₹1,911.70 each.

Is Dr. Lal Path Labs debt free?

Yes. Dr. Lal Path Labs had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹1,332 crore of cash, bank balances and current investments.

What is the Dr. Lal Path Labs debt to equity ratio?

Dr. Lal Path Labs' debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹2,541 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Dr. Lal Path Labs ROE and ROCE?

In FY26, Dr. Lal Path Labs' return on equity (ROE) was 21.6% and its return on capital employed (ROCE) was 24.8%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 24.2% and ROCE 25.7%.

What is the Dr. Lal Path Labs dividend in 2026 and its record date?

In 2026, Dr. Lal Path Labs has declared three dividends totalling ₹12.50 a share: ₹3.50 (interim) with record date 5 February 2026, ₹4 with record date 26 June 2026 and ex-date 25 June 2026 and ₹5 (interim) with record date 30 July 2026.

What is the Dr. Lal Path Labs promoter holding?

Promoters held 52.93% of Dr. Lal Path Labs on 30 September 2026, down 0.26 percentage points from 53.19% the previous quarter and down 0.28 percentage points from 53.21% a year earlier, according to the shareholding pattern filed with NSE.

What is the Dr. Lal Path Labs book value per share?

Dr. Lal Path Labs' book value per share was ₹149.65 on 31 March 2026: shareholders' equity of ₹2,508 crore divided by the 16.76 crore shares in issue. The share price at the 29 October 2026 close was ₹1,911.70.

What is the Dr. Lal Path Labs free cash flow?

In FY26, Dr. Lal Path Labs generated ₹636 crore of cash from operations and spent ₹173 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹462 crore. In FY25 it was ₹515 crore.

What are the Dr. Lal Path Labs latest quarterly results?

Dr. Lal Path Labs' latest results are for Q1 FY27 (April–June 2026), filed on 24 July 2026: consolidated net profit attributable to shareholders ₹170 crore, up 28.0% from ₹132 crore in Q1 FY26; revenue from operations ₹798 crore, up 19.1% year on year.

What is the Dr. Lal Path Labs EPS?

Dr. Lal Path Labs' basic earnings per share (EPS) were ₹30.24 in FY26.

What is the Dr. Lal Path Labs revenue and profit in FY26?

In FY26 (April 2025–March 2026), Dr. Lal Path Labs' consolidated net profit attributable to shareholders was ₹505 crore, up 3.6% from ₹487 crore in FY25, on revenue from operations of ₹2,763 crore (up 12.2%). Over three years, from FY23, net profit was up 111.3%.

When are the Dr. Lal Path Labs next results?

Dr. Lal Path Labs will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Dr. Lal Path Labs shareholding pattern?

On 30 September 2026, Dr. Lal Path Labs' shares were held by promoters 52.93%, foreign portfolio investors (FII/FPI) 18.73%, domestic institutions (DII) 21.58% (including mutual funds at 18.68%) and retail and other non-institutional investors 6.35%. Over the year, FII holding was down 3.13 percentage points from 21.86% and DII holding was up 3.09 percentage points from 18.49%.

How does the Dr. Lal Path Labs PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Dr. Lal Path Labs' PE ratio is 63.5, the second highest of the four: Metropolis Healthcare 60.4, Vijaya Diagnostic Centre 87.1 and Thyrocare Technologies 50.3, a peer average of 66.0. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Dr. Lal Path Labs vs Metropolis Healthcare: how do they compare?

In FY26, Dr. Lal Path Labs earned net profit attributable to shareholders of ₹505 crore on revenue of ₹2,763 crore, against ₹190 crore on ₹1,646 crore for Metropolis Healthcare. Dr. Lal Path Labs' operating margin was 22.5% (Metropolis Healthcare 16.2%) and its return on equity 21.6% (Metropolis Healthcare 13.4%). At the 29 October 2026 close, Dr. Lal Path Labs' market capitalisation was ₹32,040 crore against ₹11,483 crore for Metropolis Healthcare, and its PE ratio on FY26 profit 63.5 against 60.4.

How does Dr. Lal Path Labs compare with its peers?

On FY26 consolidated figures, against Metropolis Healthcare, Vijaya Diagnostic Centre and Thyrocare Technologies: Dr. Lal Path Labs' operating margin of 22.5% is the third highest of the four (Metropolis Healthcare 16.2%, Vijaya Diagnostic Centre 30.1%, Thyrocare Technologies 24.5%; peer average 23.6%); its return on equity of 21.6% is the second highest of the four (Metropolis Healthcare 13.4%, Vijaya Diagnostic Centre 19.7%, Thyrocare Technologies 28.8%; peer average 20.6%); its revenue growth over three years of 11.1% a year is the lowest of the four (Metropolis Healthcare 12.8% a year, Vijaya Diagnostic Centre 21.0% a year, Thyrocare Technologies 16.3% a year; peer average 16.7% a year).

Where do these Dr. Lal Path Labs figures come from?

From Dr. Lal Path Labs' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.